Enanta Pharmaceuticals, Inc. (ENTA) vs Orchestra BioMed Holdings, Inc. (OBIO)
A side-by-side comparison of Enanta Pharmaceuticals, Inc. and Orchestra BioMed Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ENTA
Enanta Pharmaceuticals, Inc.
$12.28HealthcareDelayed quote: Oct 6, 2026, 3:10 PM EDT
OBIO
Orchestra BioMed Holdings, Inc.
$5.88HealthcareDelayed quote: Oct 6, 2026, 3:09 PM EDT
Total return — ENTA vs OBIO
growth of $100 · dividends reinvested · last 6yENTA -73.6% (-19.9%/yr)OBIO -47.1% (-10.1%/yr)OBIO compounded faster over this window
ENTA OBIO
ENTA vs OBIO: by the numbers
- •ENTA is the larger company ($357M vs $352M market cap).
- •Both run net losses; ENTA's is the smaller (-96.89% vs -184.60% net margin).
- •OBIO grew revenue faster over the past five years (148.45% vs -7.65% CAGR).
Metrics side by side
Valuation
| Metric | ENTA | OBIO |
|---|---|---|
| P/S ratio | 5.47 | 11.01 |
| P/B ratio | 3.53 | 18.22 |
Profitability
| Metric | ENTA | OBIO |
|---|---|---|
| Gross margin | 98.15% | 99.32% |
| Operating margin | -130.65% | -154.73% |
| Net margin | -96.89% | -184.60% |
| ROE | -62.56% | -200.64% |
| ROIC | -24.20% | -56.73% |
Growth (annualized)
| Metric | ENTA | OBIO |
|---|---|---|
| Revenue CAGR (5Y) | -7.65% | 148.45% |
| Total return CAGR (5Y) | -26.94% | -9.35% |
Frequently asked
- Which has grown faster, ENTA or OBIO?
- Over the past five years, OBIO grew revenue faster — ENTA at a -7.65% CAGR versus OBIO at 148.45%.
- How have ENTA and OBIO total returns compared?
- Over the past 5 years, ENTA delivered -26.94% and OBIO delivered -9.35% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Enanta Pharmaceuticals ROEOrchestra BioMed ROEEnanta Pharmaceuticals operating marginOrchestra BioMed operating marginEnanta Pharmaceuticals revenue growthOrchestra BioMed revenue growthEnanta Pharmaceuticals free cash flowOrchestra BioMed free cash flow
Enanta Pharmaceuticals & Orchestra BioMed appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.